Pressmeddelande -
New ETVAX® data will be presented during VASE, a conference designed to spark innovation and accelerate the momentum for research and development on enteric vaccines
Despite the world’s need to focus on COVID-19, diarrheal disease has not gone away. Children are still dying and facing long-term health consequences due to this preventable illness, and new interventions are still urgently needed. The Vaccines Against Shigella and ETEC (VASE) Conference, on September 28 & 30, will provide key updates on vaccines being developed for Shigella, ETEC, and other emerging diarrheal pathogens.
The conference brings together the top minds in the enteric vaccine field; scientists, public health professionals, immunization leaders, vaccine industry representatives, international donors, and other experts around the globe who have the same mission—to share the latest research and ideas toward making enteric vaccines a reality.
While some non-COVID-19 research has had to slow down, we have important research advancements to share. 2 of the 18 presentations at VASE is highlighting our ETEC vaccine candidate ETVAX®. PI Anu Kantele, Helsinki University Hospital, will present data from our completed Phase 2b clinical trial in Benin where the excellent safety and immunogenicity of the ETVAX® was confirmed. Dr. Nsofwa Sukwa, from the Centre for Infectious Disease Research in Zambia, will present results from our recently completed phase 1 age descending study in Zambia where ETVAX ® was shown safe, tolerable, and immunogenic in Zambian adults and children.
This is really a conference for us that care about improving public health and saving lives by reducing diarrheal disease.
Ämnen
Kategorier
About Scandinavian Biopharma
Scandinavian Biopharma is a research-based specialty biopharma company determined to give people all over the world a longer and better life. Together with researchers at the University of Gothenburg and the international non-profit organization PATH, Scandinavian Biopharma is developing the first vaccine against ETEC which causes diarrhoea in both travellers and endemic populations.
The development project is mainly funded by the EDCTP programme, which is supported under Horizon 2020, the European Union’s (EU) Framework Programme for Research and Innovation, as well as by PATH and the U.S. Army (USAMMDA).
Scandinavian Biopharma also acts as a distributor for a wide range of specialty biopharma products in Europe with a focus on vaccines and immunoglobulins.
About ETEC
Enterotoxigenic Escherichia coli, or ETEC, is a major cause of bacterial diarrhoeal disease. ETEC infections are particularly common in low- and middle-income countries (LMIC). In children younger than 5 years, it has been estimated that 1.7 billion episodes of diarrhoea occur annually. ETEC represents a major cause of these episodes and accounts for approximately 400 000 deaths among children living in LMICs. In addition, diarrhoea is associated with an increased risk of stunting (i.e. impaired growth and development). Stunting affects cognitive development which might determine a child’s ability to learn, their educational attainment, and future earnings and it also puts children at risk due to other severe infectious diseases.
ETEC is also the leading cause of travellers’ diarrhoea, affecting more than 35 million travellers every year.
About ETVAX®
To date, no vaccine against ETEC exists and ETVAX® is the only ETEC vaccine candidate in late-stage development. The strong immunogenicity and safety data, as well as the promising field efficacy data, clearly distinguish ETVAX® as the lead vaccine candidate against ETEC. Successful development of this vaccine will address a huge unmet medical need for children in LMICs as well as for travellers.
